Cambrex Corporation is a Contract Development Manufacturing Organisation that provides drug substance, drug product and analytical services across the entire drug lifecycle, as well as active pharmaceutical ingredients. With over 2,200 employees in 7 countries across 13 locations, Cambrex operates in branded and generic markets for API and dosage form development and manufacturing.
Cambrex has cGMP manufacturing facilities in the US, Canada and Europe. The headquarters are located in East Rutherford, NJ.
2021 marks 40 years of Cambrex.
Cambrex was founded in 1981, when the CasChem group acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem was renamed Cambrex Corporation and became listed on NASDAQ. In 1990, Cambrex was listed on the NYSE.
Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco.
Through multiple acquisitions during the late 1990s, the firm entered the bioscience and the chiral enzymatic catalyst markets. Cambrex acquired two contract biopharmaceutical manufacturing facilities in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales. In 2007, the firm decided to focus on its core competencies and sold the biologics business to Lonza Group.
In 2008, Prosyntest was acquired, and Steve Klosk was appointed CEO, while remaining President.
Highest paying job titles at Cambrex Corporation include Process Development Scientist, Director, IT Security, and Communications Director